Literature DB >> 33891864

Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor.

Florent X Smit1, Wijnand J C van der Velden2, Hüsün S Kizilkaya2, Amalie Nørskov3, Michael Lückmann4, Tobias N Hansen3, Alexander H Sparre-Ulrich2, Katrine Qvotrup3, Thomas M Frimurer4, Mette M Rosenkilde5.   

Abstract

The glucose-dependent insulinotropic polypeptide (GIP) is a 42-residue metabolic hormone that is actively being targeted for its regulatory role of glycemia and energy balance. Limited structural data of its receptor has made ligand design tedious. This study investigates the structure and function of the GIP receptor (GIPR), using a homology model based on the GLP-1 receptor. Molecular dynamics combined with in vitro mutational data were used to pinpoint residues involved in ligand binding and/or receptor activation. Significant differences in binding mode were identified for the naturally occurring agonists GIP(1-30)NH2 and GIP(1-42) compared with high potency antagonists GIP(3-30)NH2 and GIP(5-30)NH2. Residues R1832.60, R1902.67, and R3005.40 are shown to be key for activation of the GIPR, and evidence suggests that a disruption of the K293ECL2-E362ECL3 salt bridge by GIPR antagonists strongly reduces GIPR activation. Combinatorial use of these findings can benefit rational design of ligands targeting the GIPR.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GIP; GIPR; GPCR; antagonism; class B; incretin; molecular dynamics; mutation; structural analysis; truncation

Mesh:

Substances:

Year:  2021        PMID: 33891864     DOI: 10.1016/j.str.2021.04.001

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  4 in total

1.  The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection.

Authors:  Peter Lindquist; Lærke Smidt Gasbjerg; Jacek Mokrosinski; Jens Juul Holst; Alexander Sebastian Hauser; Mette Marie Rosenkilde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

Review 2.  Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.

Authors:  Lijing Wang
Journal:  Drug Des Devel Ther       Date:  2022-05-25       Impact factor: 4.319

3.  Novel agonist and antagonist radioligands for the GLP-2 receptor. Useful tools for studies of basic GLP-2 receptor pharmacology.

Authors:  Sarina Gadgaard; Wijnand J C van der Velden; Sine P Schiellerup; Jenna Elizabeth Hunt; Maria B N Gabe; Johanne Agerlin Windeløv; Geke Aline Boer; Hannelouise Kissow; Cathrine Ørskov; Jens J Holst; Bolette Hartmann; Mette M Rosenkilde
Journal:  Br J Pharmacol       Date:  2022-01-11       Impact factor: 9.473

4.  N-terminal alterations turn the gut hormone GLP-2 into an antagonist with gradual loss of GLP-2 receptor selectivity towards more GLP-1 receptor interaction.

Authors:  Maria Buur Nordskov Gabe; Laerke Smidt Gasbjerg; Sarina Gadgaard; Peter Lindquist; Jens Juul Holst; Mette Marie Rosenkilde
Journal:  Br J Pharmacol       Date:  2022-06-08       Impact factor: 9.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.